Cross-sectional analysis of oncogenic HPV viral load and cervical intraepithelial neoplasia

International Journal of Cancer

Volumn 118, Issue 5, 2006, Pages 1187-1193

  Flores, Roberto ^a   Papenfuss, Mary ^a   Klimecki, Walter T ^b   Giuliano, Anna R ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

Cervical lesions; Human papillomavirus; Viral load

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER RISK; CARCINOGENESIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; QUANTITATIVE ASSAY; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; SQUAMOUS CELL CARCINOMA; UNITED STATES; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VIRUS INFECTION; VIRUS LOAD; WART VIRUS;

ADOLESCENT; ADULT; AGED; CERVICAL INTRAEPITHELIAL NEOPLASIA; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MIDDLE AGED; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; VIRAL LOAD;

EID: 31844451907     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.21477     Document Type: Article

References (41)

1. Ho GY, Burk RD, Fleming I, Klein S. Risk of genital human papillomavirus infection in women with human immunodeficiency virus-induced immunosuppression. Int J Cancer 1994;56:788-92.
2. Bosch FX, Munoz N, de Sanjose S, Izarzugaza I, Gili M, Viladiu P, Tormo MJ, Moreo P, Ascunce N, Gonzalez LC. Risk factors for cervical cancer in Colombia and Spain. Int J Cancer 1992;52:750-8.
3. Franco EL, Villa LL, Rahal P, Rosseau MC, Rohan TE. Risk factors for incident and persistent cervical HPV infection in a cohort of asymptomatic women. In Proceedings of the 15th International Papillomavirus Conference, Brisbane, Australia, 1996.
4. Villa LL, Sichero L, Rahal P, Caballero O, Ferenczy A, Rohan T, Franco EL. Molecular variants of human papillomavirus types 16 and 18 preferentially associated with cervical neoplasia. J Gen Virol 2000;81:2959-68.
5. Giuliano AR, Papenfuss M, Abrahamsen M, Denman C, de Zapien JG, Henze JLN, Ortega L, de Galaz EMB, Stephan J, Feng J, Baldwin S, Garcia F, et al. Human papillomavirus infection at the United States-Mexico border: implications for cervical cancer prevention and control. Cancer Epidemiol Biomarkers Prev 2001;10:1129-36.
6. de Sanjose S, Munoz N, Bosch FX, Reimann K, Pedersen NS, Orfila J, Ascunce N, Gonzalez LC, Tafur L, Gili M. Sexually transmitted agents and cervical neoplasia in Colombia and Spain. Int J Cancer 1994;56:358-63.
7. Strickler HD, Rattray C, Escoffery C, Manns A, Schiffman MH, Brown C, Cranston B, Hanchard B, Palefsky JM, Blattner WA. Human T-cell lymphotropic virus type I and severe neoplasia of the cervix in Jamaica. Int J Cancer 1995;61:23-6.
8. Sun X-W, Kuhn L, Elerbrock TV, Chiasson MA, Bush TJ, Wright TC. Human papillomavirus infection in women infected with the human immunodeficiency virus. N Engl J Med 1997;337:1343-9.
9. Ho GYF, Palan PR, Basu J, Romney SL, Kadish AS, Mikhail M, Wassertheil-Smoller S, Runowicz C, Burk RD. Viral characteristics of human papillomavirus infection and antioxidant levels as risk factors for cervical dysplasia. Int J Cancer 1998;78:594-9.
10. Peng H, Liu S, Mann V, Rohan T, Rawls W. Human papillomavirus types 16 and 33, herpes simplex virus type 2 and other risk factors for cervical cancer in Sichuan Province, China. Int J Cancer 1991;47:711-6.
11. Sun CA, Lai HC, Chang CC, Neih S, Yu CP, Chu TY. The significance of human papillomavirus viral load in prediction of histologic severity and size of squamous intraepithelial lesions of uterine cervix. Gynecol Oncol 2001;83:95-9.
12. Sun CA, Liu JF, Wu DM, Nieh S, Yu CP, Chu TY. Viral load of high-risk human papillomavirus in cervical squamous intraepithelial lesions. Int J Gynaecol Obstet 2002;76:41-7.
13. Cuzick J, Terry G, Ho L, Hollingworth T, Anderson M. Type-specific human papillomavirus DNA in abnormal scrapes as a predictor of high-grade cervical intra-epithelial neoplasia. Br J Cancer 1994;69:167-71.
14. Beskow AH, Gyllensten UB. Host genetic control of HPV 16 titer in carcinoma in situ of the uterine cervix. Int J Cancer 2002;101:526-31.
15. Joseffson AM, Magnusson PKE, Ylitalo N, Soensen P, Andersen PK, Melbye M, Adami HO, Gyllenstein UB. Viral load of human papillomavirus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study. Lancet 2000;355:2189-93.
16. Ylitalo N, Sorensen P, Josefsson MA, Magnusson PKE, Andersen PK, Ponten J, Adai HO, Gyllensten UB, Melbye M. Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: a nested case-control study. Lancet 2000;355:2194-8.
17. Swan DC, Tucker RA, Tortolero-Luna G, Mitchell MF, Wideroff L, Unger ER, Nisenbaum RA, Reeves WC, Icenogle JP. Human papillomavirus (HPV) DNA copy number is dependent on grade of cervical disease and HPV type. J Clin Microbiol 1999;37:1030-4.
18. Schlecht NF, Trevisan A, Duarte-Franco E, Rohan TE, Ferenczy A, Villa LL, Franco EL. Viral load as a predictor of the risk of cervical intraepithelial neoplasia. Int J Cancer 2003;103:519-24.
19. Lorincz AT, Castle PE, Sherman ME, Scott DR, Glass AG, Wacholder S, Rush BB, Gravitt PE, Schussler JE, Schiffman M. Viral load of human papillomavirus and risk of CIN3 or cervical cancer. Lancet 2002;360:228-9.
20. Bory JP, Cucherousset J, Lorenzato M, Gabriel R, Quereux C, Birembaut P, Clavel C. Recurrent human papillomavirus infection detected with the hybrid capture II assay selects women with normal cervical smears at risk for developing high grade cervical lesions: a longitudinal study of 3,091 women. Int J Cancer 2002;102:519-25.
21. Sherman ME, Wang SS, Wheeler CM, Rich L, Gravitt PE, Tarone R, Schiffman M. Determinants of human papillomavirus load among women with histological cervical intraepithelial neoplasia 3: dominant impact of surrounding low-grade lesions. Cancer Epidemiol Biomarkers Prev 2003;12:1038-44.
22. Castle PE, Schiffman M, Wheeler CM. Hybrid capture 2 viral load and the 2-year cumulative risk of cervical intraepithelial neoplasia grade 3 or cancer. Am J Obst Gynecol 2004;191:1590-7.
23. Castle PE, Schiffman M, Scott DR, Sherman ME, Glass AG, Rush BB, Schussler JE, Wacholder S, Lorincz A. Semiquantitative human papillomavirus type 16 viral load and the prospective risk of cervical precancer and cancer. Cancer Epidemiol Biomarkers Prev 2005;14:1311-4.
24. Moberg M, Gustavsson I, Gyllensten U. Type-specific associations of human papillomavirus load with risk of developing cervical carcinoma in situ. Int J Cancer 2004;112:854-9.
25. Giuliano AR, Denman C, de Zapien J, Henze JL, Ortega L, Djambazob B, de Galaz E, Hatch K, the Cervical Cancer Binational Team. Design and results of the USA-Mexico border Human Papillomavirus (HPV), cervical dysplasia, and Chlamydia trachomatis study. Rev Panam Salud Publica/Pan Am J Pub Health 2001;9:172-81.
26. Gravitt PE, Peyton CL, Allessi T, Wheeler C, Coutlee F, Hildesheim A, Schiffman M, Scott D, Apple R. Improved amplification of genital human papillomaviruses. J Clin Microbiol 2000;38:357-61.
27. Gravitt PE, Peyton CL, Apple RJ, Wheeler CM. Genotyping of 27 human papillomavirus types by using L1 consensus PCR products by a single hybridization, reverse line blot detection method. J Clin Microbiol 1998;36:3020-7.
28. Flores-Munguia R, Siegel E, Klimecki WT, Giuliano AR. Performance assessment of eight high throughput real-time PCR assays for viral load quantification of oncogenic HPV types. J Mol Diagn 2004;6:115-24.
29. Tucker RA, Unger E, Holloway BP, Swan DC. Real-time PCR-based fluorescent assay for quantitation of human papillomavirus types 6, 11, 16 and 18. Mol Diagn 2001;6:39-47.
30. Van Duin M, Snijders PJF, Schrijnrmakers HJF, Voorhorst FJ, Rozendaal L, Nobbenhuis MAE, Van den Brule AJC, Verheijen RHM, Helmerhost TJ, Meijer C. Human Papillomavirus 16 load in normal and abnormal cervical scrapes: an indicator of CIN II/III and viral clearance. Int J Cancer 2002;98:590-5.
31. Giuliano AR, Papenfuss M, Mendez-Brown de Galaz E, Feng J, Abrahamsen M, Denman C, Guernsey de Zapien J, Navarro-Henze JL, Garcia F, Hatch K. Risk factors for squamous intraepithelial lesions (SIL) of the cervix among women residing at the US-Mexico border. Int J Cancer 2004;109:112-8.
32. Sherman ME, Schiffman M, Cox JT. Effects of age and HPV viral load on colposcopy triage: data from the randomized atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion triage study (ALTS). J Natl Cancer Inst 2002;94:102-7.
33. Fife KH, Cramer HM, Schroeder JM, Brown DR. Detection of multiple human papillomavirus types in the lower genital tract correlates with cervical dysplasia. J Med Virol 2001;64:550-9.
34. Moberg M, Gustavsson I, Wilander E, Gyllensten U. High viral loads of human papillomavirus predict risk of invasive cervical carcinoma. Br J Cancer 2005;92:891-4.
35. Levi JE, Fernandes S, Tateno AF, Motta E, Lima LP, Eluf-Neto J, Pannuti CS. Presence of multiple human papillomavirus types in cervical samples from HIV-infected women. Gynecol Oncol 2004;92:225-31.
36. An HJ, Cho NH, Lee SY, Kim IH, Lee C, Kim SJ, Mun MS, Kim SH, Jeong JK. Correlation of cervical carcinoma and precancerous lesions with human papillomavirus (HPV) genotypes detected with the HPV DNA chip microarray method. Cancer 2003;97:1672-80.
37. Peitsaro P, Johansson B, Syrjanen S. Integrated human papillomavirus type 16 is frequently found in cervical cancer precursors as demonstrated by a novel quantitative real-time PCR technique. J Clin Microbiol 2002;40:886-91.
38. Franco EL. Primary screening of cervical cancer with human papillomavirus tests. J Natl Cancer Inst Monogr 2003;31:89-96.
39. Hudelist G, Manavi M, Pischinger KID, Watkins-Riedel T, Singer CF, Kubista E, Czerwenka KF. Physical state and expression of HPV DNA in benign and dysplastic cervical tissue: different levels of viral integration are correlated with lesion grade. Gynecol Oncol 2004;92:873-80.
40. Crook T, Fisher C, Masterson PJ, Vousden KH. Modulation of transcriptional regulatory properties of p53 by HPV E6. Oncogene 1994;9:1225-30.
41. Middleton K, Peh W, Southern S, Griffin H, Sotlar K, Nakahara T, El-Sherif A, Morris L, Seth R, Hibma M, Jenkins D, Lambert P, et al. Organization of human papillomavirus productive cycle during neoplastic progression provides a basis for selection of diagnostic markers. J Virol 2003;77:10186-201.